FRANKLIN LAKES, N.J. — To recognize National Diabetes Awareness Month in November, embecta, one of the largest diabetes care companies in the world, will ring the NASDAQ opening bell on November 1 along with advocacy partners Beyond Type 1, Camp Nejeda, DiabetesSisters and The Diabetes Link.
embecta spun off from BD in April 2022 and president and CEO Dev Kurdikar has spent the last six months focused on:
- Building on embecta’s foundation as the leading producer of diabetes injection devices
- Enhancing its internal infrastructure and positioning the company for both organic and inorganic growth
- Advancing the development of a Type 2 insulin delivery system utilizing proprietary patch pump, which carries Breakthrough Device Designation from the U.S. Food & Drug Administration.
Despite a challenging macro-economic environment, embecta has delivered a strong financial performance since its launch as an independent company.
embecta employs more than 2,000 people around the globe and manufactures more than 75% of the world’s insulin syringes.